PROTEOMIC PROFILE CORRELATES TO MOLECULAR RESPONSE (MR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)

被引：0
|
作者：
Sgherza, N. [1 ,2 ]
Garrisi, V. M. [3 ]
Iacobazzi, A. [4 ]
Abbate, I. [3 ]
Cascavilla, N. [1 ,2 ]
Guarini, A. [4 ]
机构：
[1] Osped Casa Sollievo Sofferenza IRCCS, Ematol, San Giovanni Rotondo, Fg, Italy
[2] Osped Casa Sollievo Sofferenza IRCCS, Ctr Trapianto Cellule Staminali, San Giovanni Rotondo, Fg, Italy
[3] Ist Tumori Giovanni Paolo II, IRCCS, UOC Ematol, Bari, Italy
[4] Ist Tumori Giovanni Paolo II, IRCCS, Lab Patol Clin & Sperimentale, Bari, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P076
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [31] Granulocytes from chronic myeloid leukemia (CML) patients show differential response to different chemoattractants
    Radhika, V
    Thennarasu, S
    Naik, NR
    Kumar, A
    Advani, SH
    Bhisey, AN
    AMERICAN JOURNAL OF HEMATOLOGY, 1996, 52 (03) : 155 - 164
  • [32] Deep and early molecular response induced by nilotinb in a newly diagnosed patient with chronic myeloid leukemia (CML)
    Rossi, Antonella Russo
    CLINICAL MANAGEMENT ISSUES, 2013, 7 : 19 - 23
  • [33] Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?
    Verma, Dushyant
    Kantarjian, Hagop M.
    Shan, Jenny
    O'Brien, Susan
    Verma, Amit
    Jabbour, Elias
    Verstovsek, Srdan
    Kadia, Tapan
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 208 - 209
  • [34] Deep molecular response in chronic myeloid leukemia
    N C P Cross
    A Hochhaus
    Leukemia, 2016, 30 : 1632 - 1632
  • [35] Concomitant or Sequential Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid Leukemia (CML): A Molecular and Clinical Survey
    Said, Carla
    Heimann, P.
    Dessars, B.
    Phong, Dinh
    Cantiniaux, B.
    Cantiniaux, B.
    Meuleman, N.
    Bron, D.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (06): : E34 - E34
  • [36] PREDICTORS OF DEEP MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE: AN ANALYSIS BY THE GIMEMA CML WP
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Specchia, G.
    Binotto, G.
    Abruzzese, E.
    Iurlo, A.
    Vigneri, P.
    Cavazzini, F.
    Intermesoli, T.
    Ferrero, D.
    Martino, B.
    Leoni, P.
    Bocchia, M.
    Rege-Cambrin, G.
    Gherlinzoni, F.
    Bochicchio, M. T.
    Soverini, S.
    Alimena, G.
    Pane, F.
    Saglio, G.
    Cavo, M.
    Martinelli, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2015, 100 : 324 - 324
  • [37] Monitoring Molecular Response in Chronic Myeloid Leukemia
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    CANCER, 2011, 117 (06) : 1113 - 1122
  • [38] Deep molecular response in chronic myeloid leukemia
    Cross, N. C. P.
    Hochhaus, A.
    LEUKEMIA, 2016, 30 (07) : 1632 - 1632
  • [39] Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
    Shah, Neil P.
    Gutierrez, Jose Valentin Garcia
    Jimenez-Velasco, Antonio
    Larson, Sarah M.
    Saussele, Susanne
    Rea, Delphine
    Mahon, Francois-Xavier
    Levy, Moshe
    Gomez-Casares, Maria Teresa
    Pane, Fabrizio
    Nicolini, Franck-Emmanuel
    Mauro, Michael J.
    Sy, Oumar
    Martin-Regueira, Patricia
    Lipton, Jeffrey H.
    BLOOD, 2017, 130
  • [40] BCR-ABL Fluctuation in Chronic Myeloid Leukemia (CML) Patients with Deep Molecular Response (MR): What is the Meaning of a Big Wave when You Test the Patients in Different Laboratories?
    Pinto, Mariana
    Bosi, Guilherme
    Costa, Tito
    Grokoski, Kamila
    Kramer, Andrea
    Abkalil, Marco
    Fogliatto, Laura
    Silla, Lucia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S316 - S317
12345